Krystal Biotech, Inc. (KRYS)

Krystal Biotech's stock has been impacted by strong Q3 2025 earnings, which exceeded analysts' expectations. Several investment banks reiterated "Buy" ratings and raised price targets. The stock reached an all-time high in January 2026. However, Zacks Research downgraded Krystal Biotech from a "strong-buy" to a "hold" rating in February 2026.

Information regarding specific demand seasonality for Krystal Biotech's products and services is not readily available.

Krystal Biotech is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines for rare diseases. Their flagship product is VYJUVEK, a redosable gene therapy approved for dystrophic epidermolysis bullosa (DEB). The company is also advancing a pipeline of genetic medicine candidates, including KB105, KB104, KB407, KB707, KB408, and KB301.

Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, United States. VYJUVEK has been approved in the United States, Europe, and Japan for the treatment of DEB.

Krystal Biotech has maintained a positive brand reputation, driven by positive analyst sentiment and product advancements. The company has received a consensus "Buy" rating from numerous brokerages. Key positive events include the European Commission and Japan approvals of VYJUVEK, and the FDA granting platform technology designation to Krystal Biotech's HSV-1 viral vector. Impending competition for VYJUVEK from Abeona Therapeutics' pz-cel contributed to a stock pullback in July 2024.

Krystal Biotech has a significant number of institutional owners, holding a total of 33,366,329 shares. Major institutional shareholders include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Individual insider ownership accounts for 13.70% of the stock, with founders Krish Krishnan and Suma Krishnan being notable individual owners.